Susquehanna International Group, LLP Incyte Corp Put Options Transaction History

Susquehanna International Group, LLP

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$57.33 - $68.61 $177,723 - $212,691	-3,100 Reduced 2.26%	133,800 $8.84 Million
Q2 2024 Aug 15, 2024	BUY	$51.18 - $63.75 $1.19 Million - $1.48 Million	23,200 Added 20.4%	136,900 $8.3 Million
Q1 2024 May 07, 2024	BUY	$56.55 - $66.59 $5.41 Million - $6.37 Million	95,700 Added 531.67%	113,700 $6.48 Million
Q4 2023 Feb 14, 2024	SELL	$52.16 - $64.19 $3.01 Million - $3.71 Million	-57,800 Reduced 76.25%	18,000 $1.13 Million
Q3 2023 Nov 14, 2023	SELL	$57.77 - $65.93 $1.36 Million - $1.56 Million	-23,600 Reduced 23.74%	75,800 $4.38 Million
Q2 2023 Aug 11, 2023	BUY	$60.95 - $75.51 $4.78 Million - $5.92 Million	78,400 Added 373.33%	99,400 $6.19 Million
Q1 2023 May 16, 2023	SELL	$70.23 - $86.01 $4.1 Million - $5.02 Million	-58,400 Reduced 73.55%	21,000 $1.52 Million
Q4 2022 Feb 14, 2023	BUY	$67.18 - $84.11 $2.3 Million - $2.88 Million	34,300 Added 76.05%	79,400 $6.38 Million
Q3 2022 Nov 14, 2022	SELL	$66.18 - $82.86 $1.11 Million - $1.38 Million	-16,700 Reduced 27.02%	45,100 $3.01 Million

644

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $15.4B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.